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neuropathology. RT-QuIC showed an overall diagnostic 
sensitivity of 82.1% and a specificity of 99.4%. However, 
sensitivity was lower in CJD types linked to abnormal 
prion protein (PrPSc) type 2 (VV2, MV2K and MM2C) 
than in typical CJD (MM1). Among surrogate proteins 
markers (14-3-3, total (t)-tau, and t-tau/phosphorylated 
(p)-tau ratio) t-tau performed best in terms of both specific-
ity and sensitivity for all sCJD types. Sporadic CJD VV2 
and MV2K types demonstrated higher CSF levels of p-tau 
when compared to other sCJD types and this positively cor-
related with the amount of tiny tau deposits in brain areas 
showing spongiform change. CJD patients showed moder-
ately reduced median Aβ42 CSF levels, with 38% of cases 
having significantly decreased protein levels in the absence 
of Aβ brain deposits. Our results: (1) support the use of 
both RT-QuIC and t-tau assays as first line laboratory 
investigations for the clinical diagnosis of CJD; (2) dem-
onstrate a secondary tauopathy in CJD subtypes VV2 and 
MV2K, correlating with increased p-tau levels in the CSF 
and (3) provide novel insight into the issue of the accuracy 
of CSF p-tau and Aβ42 as markers of brain tauopathy and 
β-amyloidosis.
Keywords Human prions · Biomarkers · RT-QuIC · 
Amyloid-beta · Tauopathy · Alzheimer’s disease · Protease-
sensitive prionopathy
Introduction
Human prion diseases, also known as transmissible spongi-
form encephalopathies (TSE), are rapidly progressive neu-
rodegenerative disorders caused by prion protein misfold-
ing [57]. With an annual incidence of ~2 cases per million 
persons sporadic Creutzfeldt-Jakob disease (sCJD) is by 
Abstract The differential diagnosis of Creutzfeldt-Jakob 
disease (CJD) from other, sometimes treatable, neurologi-
cal disorders is challenging, owing to the wide phenotypic 
heterogeneity of the disease. Real-time quaking-induced 
prion conversion (RT-QuIC) is a novel ultrasensitive 
in vitro assay, which, at variance with surrogate neurode-
generative biomarker assays, specifically targets the path-
ological prion protein (PrPSc). In the studies conducted to 
date in CJD, cerebrospinal fluid (CSF) RT-QuIC showed 
good diagnostic sensitivity (82–96%) and virtually full 
specificity. In the present study, we investigated the diag-
nostic value of both prion RT-QuIC and surrogate pro-
tein markers in a large patient population with suspected 
CJD and then evaluated the influence on CSF findings of 
the CJD type, and the associated amyloid-β (Aβ) and tau 
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far the most common form (85–90% of cases) [53], fol-
lowed by genetic CJD (gCJD) and fatal familial insomnia 
(10–15% of cases), which are linked to point or insertion 
mutations in the prion protein gene (PRNP) [14]. Rare 
acquired forms of CJD caused by human to human or ani-
mal to human transmission of infectious prions [74], and 
atypical disease variants with a slower progression, such 
as Gerstmann-Sträussler-Scheinker syndrome (GSS), prion 
protein-cerebral amyloid angiopathy (PrP-CAA) and vari-
ably protease-sensitive prionopathy (VPSPr) complete the 
phenotypic spectrum of human prion diseases of the CNS 
[25, 81].
CJD is increasingly recognised in the differential diag-
nosis of rapidly progressive neurological syndromes, high-
lighting the need for reliable tools to provide an early clini-
cal diagnosis [23, 33, 61, 62]. The ageing population, the 
improved awareness of CJD as a heterogeneous disorder 
covering a wider phenotypic spectrum than previously rec-
ognised [53], and the identification of potentially treatable 
disorders that manifest as rapidly progressive dementia 
(RPD) [8, 16, 24] have all contributed to this scenario.
Current diagnostic criteria for sCJD [80] were mainly 
developed for epidemiological purposes and do not take 
into account the extent of clinical heterogeneity shown by 
sCJD patients. This is a major cause of the difficulties in 
the clinical diagnosis and differentiation of prion diseases 
against other neurological disorders. Currently, at least six 
major subtypes of sCJD are recognised, which are largely 
determined by the genotype at the polymorphic codon 129 
(encoding methionine, M or valine, V) in PRNP, and by the 
type (type 1 or type 2) of PrPSc accumulating in the brain 
[50, 52]. The number and variety of clinical symptoms 
(especially at onset), the rate of disease progression, and 
the underlying regional brain pathology vary significantly 
among sCJD subtypes; this affects the relative accuracy of 
the proposed diagnostic criteria.
CSF protein assays combined with special MRI tech-
niques such as FLAIR and DWI currently represent the 
most useful in vivo markers for sCJD [13, 78]. Specifically, 
several brain-derived CSF proteins serving as surrogate 
markers for neuronal damage have been considered, alone 
or in combination, for their utility in supporting the clini-
cal diagnosis of probable CJD. Among them, CSF protein 
assays for 14-3-3, t-tau and p-tau (for the calculation of the 
t-tau/p-tau ratio) have contributed the most promising and 
significant results regarding sensitivity and specificity in 
distinguishing CJD from other RPDs, although with a sig-
nificant heterogeneity both in terms of number of studies 
and agreement regarding the relative performance of each 
assay [6, 9, 12, 17, 18, 22, 30, 44, 48, 60, 63, 67, 68, 72, 
79]. More recently, the development of the RT-QuIC assay 
[5], an in vitro fluorimetric assay which is able to indirectly 
detect very low amounts of prions, based on the capacity 
of PrPSc to induce recombinant (rec-) PrP conversion and 
aggregation, has provided a very promising tool to improve 
the early diagnosis of human prion diseases in a notewor-
thy manner given its high degree of sensitivity (82–97%) 
and specificity (99–100%) [5, 19, 41, 45, 46, 55, 64].
The evaluation of biomarker accuracy for an early clini-
cal diagnosis should be ideally conducted on a clinically 
based cohort of patients with RPD in which the clinical 
suspicion of prion disease was raised. Nevertheless, only a 
few studies considered this approach [6, 9, 17, 48, 62, 71, 
80]. Furthermore, only a portion of previous studies spe-
cifically analysed the effect of the disease subtype on the 
sensitivity and specificity of the available biomarker assays 
[15, 28, 30, 35, 38, 48, 63, 77]. Finally, knowledge about 
the reliability of measuring CSF proteins such as p-tau and 
Aβ42 to predict the underlying neuropathology is based on 
a limited number of studies that often used post-mortem 
ventricular CSF or brain biopsies to maintain the time lapse 
between CSF and brain assessment at minimum [11, 65, 
69, 70]. In this respect, brains affected by CJD provide the 
unique opportunity to correlate the CSF findings with the 
post-mortem neuropathology within a short time interval.
In the present study, we aimed to investigate the util-
ity of several CSF biomarkers (14-3-3, t-tau, p-tau, Aβ42 
and rec-PrP seeded conversion by RT-QuIC) in the differ-
ential diagnosis of CJD from other neurological disorders, 
in a large non-selected clinical population suspected to be 
affected by a prion disease. Furthermore, we assessed the 
diagnostic accuracy (specificity and sensitivity) of each 
assay employed in the present study, also considering the 
molecular subtypes in sporadic cases and the mutation type 
in genetic CJD patients. Finally, in definite CJD cases we 
correlated the CSF findings concerning p-tau and Aβ42 
with the type and amount of tau and Aβ pathology in the 
brain.
Materials and methods
Inclusion criteria and case classification
We analyzed CSF samples from 1062 patients presenting 
with a progressive neurological syndrome which prompted 
the inclusion of CJD in the differential diagnosis at time 
of lumbar puncture (LP). Samples were from consecutive 
cases submitted for diagnostic purposes between January 
2003 and June 2016, and were analyzed at the Laboratory 
of Neuropathology (NP-Lab) of the Institute of Neurologi-
cal Sciences of Bologna (ISNB), a major reference labora-
tory for prion disease in Italy.
A clinical history of current and past illnesses, peri-
odically updated up to the time of the last data analysis 
(November 2016), as well as the results of EEG and brain 
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MRI studies, were acquired for each patient. Follow-up 
clinical data were obtained with the combined effort of 
neurologists at the ISNB and those at the National CJD 
Surveillance Unit in Rome. Based on the available clini-
cal, laboratory (EEG and MRI) and neuropathological data, 
patients were classified at the time of data analysis in diag-
nostic categories according to the updated WHO criteria 
for the diagnosis of CJD and related disorders [80] with a 
modification concerning the categories “possible” (see also 
below) and “probable” CJD, mainly because no CSF bio-
marker data were used for case classification. Specifically, 
four major groups were considered for the data analysis: 
“definite” CJD (n = 233), which included all prion positive 
cases at post-mortem examination (186 sCJD + 17 gCJD 
+1 VPSPr) and the genetic cases carrying a pathogenic 
PRNP mutation who had no autopsy (n = 29), “probable” 
CJD (n = 97), consisting of patients fulfilling the clini-
cal criteria for possible CJD and showing either a positive 
EEG or a positive MRI or both, “possible” CJD (n = 29), 
comprising patients in which the primary clinical diagnosis 
after follow-up remained CJD despite the lack of a posi-
tive EEG or MRI, and the “non-CJD” (n = 703). The latter 
included: (1) 586 patients in whom an alternative diagnosis 
to prion disease was given, either by post-mortem neuro-
pathological examination (n = 81) or by clinical criteria 
(n = 505), and (2) 117 patients not fulfilling the clinical 
criteria for possible CJD but lacking an alternative diagno-
sis. Among them 38 showed significant clinical improve-
ment at follow-up, 41 suffered from cognitive decline or 
disturbances of vigilance without associated neurological 
signs, 24 had a total disease duration longer than 2 years, 
while for the remaining 14 cases clinical information were 
too scanty to reach a reliable classification. However, none 
of these 14 cases showed a positive CSF assay (14-3-3, 
t-tau, or RT-QuIC).
Finally, a subgroup of “definite” non-CJD cases 
(n = 212), including those that were prion negative at 
post-mortem examination (n = 81), those showing a 
clinical evolution incompatible with a prion disease (e.g., 
improvement or stabilization at follow-up) (n = 61, includ-
ing 21 cases with a clinical diagnosis of encephalitis and 
2 of metabolic encephalopathy), and those with an alter-
native “definitive” clinical diagnosis (e.g., strongly sup-
ported by genetic, neuroradiological and/or laboratory 
findings) (n = 70), was also considered for a more accu-
rate calculation of the specificity of the diagnostic tests. 
Specifically, the group with a “definitive” clinical diagno-
sis included patients with: (1) a neurodegenerative disease 
(n = 7), either carrying a pathogenic mutation (1 Alzhei-
mer’s disease (AD), 2 fronto-temporal dementia (FTD), 1 
Lewy body dementia and 2 Huntington’s disease) or with 
a clinico-neuroradiological diagnosis (1 superficial sidero-
sis of CNS), (2) a clinico-neuroradiological diagnosis of 
stroke (n = 7), (3) a paraneoplastic syndrome confirmed 
by the finding of a systemic tumor and/or the presence of 
anti-(onco)neuronal antibodies in serum and CSF (n = 20), 
(4) a laboratory proven (presence of membrane-associated 
antineuronal antibodies in CSF) non-paraneoplastic auto-
immune encephalitis (n = 9), (5) a laboratory confirmed 
diagnosis of an infectious encephalitis (n = 8), with a 
clinico-neuroradiological diagnosis of CNS malignancy 
(n = 8), with a clinico-neuroradiological diagnosis of met-
abolic encephalopathy (n = 4), with a psychiatric diagnosis 
(n = 4) and with other rare diseases (n = 3).
The clinical diagnosis of AD was made according to 
the 2011 National Institute on Aging and the Alzheimer’s 
Association workgroup guidelines [43]. In particular, after 
a clinical follow-up of at least 24 months, all 101 patients 
with a clinical diagnosis of AD fulfilled criteria for proba-
ble AD dementia with high or intermediate evidence of the 
AD patho-physiological process.
The study was conducted according to the revised Dec-
laration of Helsinki and Good Clinical Practice guidelines. 
Informed consent was given by study participants or their 
next of kin.
Molecular genetic analysis
To identify cases carrying mutations and to determine the 
genotype at the polymorphic codon 129 of the PRNP gene, 
we carried out a molecular analysis in all subjects with a 
definite, probable or possible diagnosis of prion disease 
(n = 359), as previously described [32]. Furthermore, all 
cases with a positive familial history for dementia and those 
with a clinical history compatible with early onset neurode-
generative dementia (<60 years) were also screened for var-
iants in 22 dementia-associated genes, using the Illumina 
MiSeq sequencer with the amplicon-based assay TruSeq 
Custom Amplicon v1.5 (TSCA, Illumina), as described 
by Beck et al. [7]. Major screened genes included PSEN1, 
PSEN2, APP, PRNP, GRN, MAPT, and FUS.
CSF biochemical analysis
CSF samples were collected by LP following a standard 
procedure, centrifuged at 1000×g for 10 min and stored in 
polypropylene tubes at −80 °C until analysis.
14‑3‑3 protein detection
For this assay, which was performed in all samples 
(n = 1062), 10 µl of CSF were mixed with loading buffer, 
containing 4 mM EDTA, 6% (w/v) sodium dodecyl sul-
phate (SDS), 20% glycerol (w/v) and 50 mM Tris–HCl 
(pH 6.8), heated for 5 min at 100 °C. Proteins were then 
separated by SDS-PAGE on a 13% gel and transferred to 
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a polyvinylidene fluoride (PVDF) membrane. After blot-
ting, the PVDF membrane was blocked for 60 min with 
10% (w/v) non-fat dry milk powder in Tris-buffered saline 
with 0.1% Tween-20, and incubated overnight at 4 °C 
with pan-anti-14-3-3 rabbit polyclonal primary antibody 
sc-629 (1:200, Santa Cruz Biotechnology, Inc). The mem-
brane was then incubated for 1 h at room temperature with 
an anti-rabbit horseradish peroxidase-linked secondary 
immunoglobulin diluted 1:3000. The immunoreactive sig-
nal was detected by enhanced chemiluminescence on an 
LAS 3000 camera. Western blot signals were measured by 
densitometry using AIDA software.
Two CSF controls (with a weak or a strong 14-3-3 sig-
nal, respectively) were loaded in duplicate on every gel 
together with the CSF samples. The immunoreactivity sig-
nals were rated as negative, ambiguous or positive, on the 
basis of the optical densitometric (OD) comparison with 
the weakly positive control. In particular, the 14-3-3 signal 
was classified as negative when the 14-3-3 band OD was 
lower than the control, ambiguous (or weakly positive) 
when the 14-3-3 OD was up to two times higher than the 
control, and positive when it was at least two times higher 
than the control. This decision point was chosen after 
having analysed the test predictive value at different den-
sitometry value ranges. To maintain a consistent cut-off 
value determined by the OD of the weakly positive control 
throughout the whole study, we pooled several CSF sam-
ples, aliquoted and stored them at −80 °C until analysis. 
Furthermore, a systematic comparison of densitometry 
values between control samples was performed each time 
a new pooled control sample was introduced, which hap-
pened four times during the study.
T‑tau, p‑tau (181P) and Aβ42 protein quantification
These three proteins were quantitatively analysed using 
commercially available kits based on a sandwich ELISA 
method, according to the manufacturer’s instructions 
(INNOTEST, Innogenetics, Gent, Belgium). While the 
CSF concentration of t-tau was measured in all patients 
(n = 1062), p-tau and Aβ42 assays were performed in sub-
groups of, respectively, 605 (294 CJD and 311 non-CJD, 
including 85 AD) (see also Suppl. Table 1) and 339 (208 
CJD and 131 non-CJD, including 71 AD) cases. For Aβ42, 
however, the actual number of samples used for group 
comparison and neuropathological correlates of CSF pro-
tein level was lower (see also paragraph on effect of stor-
age time and Suppl. Table 1). Based on receiver operating 
characteristic (ROC) curve analysis, the cut-off value cho-
sen for t-tau was 1250 pg/ml, whereas a p-tau level >60 pg/
ml and an Aβ42 level <450 pg/ml were considered abnor-
mal based on internal normative values. Specifically, at 
1250 pg/ml t-tau reached an area under the curve (AUC) 
of 0.949 ± 0.07. The optimal cut-off value was chosen 
after analysing the distribution of sensitivity and specific-
ity at different decision points and calculated as 1250 pg/ml 
based on maximum potential effectiveness (Youden index, 
0.78). At this decision point, the sensitivity and specific-
ity were, respectively, 89.4 and 88.1%. The between-assay 
coefficients of variation for the t-tau, p-tau and Aβ42 tests 
were, respectively, 10.0, 9.1 and 13.0%, as determined by 
internal control samples during the study period. The labo-
ratory performing the analyses participates to the Alzhei-
mer’s Association quality control program on CSF bio-
markers [40].
PrPSc detection by RT‑QuIC
This assay was performed in a subgroup of 700 samples 
including 179 definite sCJD, 1 VPSPr, 46 gCJD, 97 prob-
able CJD, 29 possible CJD, and 348 non-CJD control 
patients affected by other neurological disorders (Table 1).
CSF samples were analyzed by the RT-QuIC assay 
as previously described [41], with minor modifications. 
Briefly, the RT-QuIC reaction mix contained 10 mM phos-
phate buffer at pH 7.4, 300 mM NaCl, 1 mM EDTA at pH 
8.0, 10 μM thioflavin-T (ThT) and 0.1 mg/ml of Syrian 
hamster recombinant full-length prion protein (Ha rPrP 
23-231, supplied by Bristol Institute of Blood Sciences, 
Bristol, UK) [41]. All the reaction solutions were freshly 
prepared and filtered before use with 0.22 µm sterile fil-
ters. For this assay, 15 µl of each CSF sample was added 
in the dark to 85 µl of reaction mix in black clear-bottom 
96-well micro plates. Samples were tested in quadrupli-
cate together with a positive (definite CJD) and a negative 
(non-CJD) control. After sealing, the plate was incubated 
in a FLUOstar OPTIMA reader at 42 °C, over a period of 
120 h with intermittent cycles of shaking (60 s, 700 rpm, 
double-orbital) and rest (60 s). The fluorescence intensity 
of ThT-PrPSc aggregates, expressed as relative fluorescence 
units (rfu), was taken every 45 min using 450 ± 10 nm 
(excitation) and 480 ± 10 nm (emission) wavelengths, with 
a bottom read. A CSF sample was considered prion positive 
if the mean of at least two out four sample replicates gave 
a fluorescence signal higher than the threshold cut-off value 
of 7000 rfu. This threshold represents the mean rfu values 
of negative samples plus at least five standard deviations. 
Samples were considered negative if none of the replicates 
surpassed the chosen cut-off. In case only one replicate 
went over the threshold, the test was considered ambigu-
ous/unclear and repeated.
Analysis of the effect of CSF storage time
In the present study, the results of CSF proteins 14-3-3 and 
t-tau assays have been analyzed prospectively. Samples 
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were sent for diagnostic purposes and the results obtained 
within a 2–3 week time frame for both assays. At variance, 
p-tau, Aβ42 and RT-QuIC assays were implemented in the 
lab at later times (2011 for p-tau and Aβ42, 2013 for the 
RT-QuIC). As a consequence, samples were analysed in 
these assays at various times after collection. To determine 
whether the length of storage had an effect on the results 
of these assays, we compared the results obtained between 
groups of samples with increasing storage times. While we 
found that the length of storage has no effect on p-tau and 
RT-QuIC (see Suppl. Table 2), a significant effect (signifi-
cantly lower protein levels) was seen on Aβ42 in the group 
with the longest storage time (>5 years). We, therefore, 
limited the analysis of the results of the Aβ42 assay to the 
samples with a storage time up to 5 years (n = 285, 164 
CJD and 121 non-CJD).
Neuropathological analysis
According to a standardized protocol which is used nation-
wide for prion suspected cases, the right half of the brain is 
immediately frozen, stored at −80 °C, while the other half 
(left) is fixed in formalin. Once received by the reference 
lab (NP-Lab at ISNB), the frozen cerebral and cerebellar 
hemispheres are cut in coronal sections, and then both the 
frozen and fixed halves are regionally sampled according to 
standardized procedures.
Histopathological examination was performed on 7 μm 
thick sections of formalin-fixed and paraffin-embedded 
brain tissue blocks. Sections were systematically taken 
from neo-cortical areas (two for each lobe), limbic cortices 
(cingulate and insular cortices), basal ganglia (anterior and 
posterior), thalamus (anterior and posterior), hippocam-
pus (anterior and posterior), amygdala and basal forebrain, 
midbrain, pons, medulla oblongata and cerebellum (vermis 
and hemisphere with and without dentate nucleus). Tissues 
(PrPSc positive at Western blotting) were processed after 
decontamination for 1 h in concentrated formic acid (98%). 
For screening, haematoxylin–eosin stain was performed 
on all sections according to a standard procedure. Evalua-
tion of spongiform change and immunohistochemical PrP 
deposits was carried out in all cases of neuropathologically 
confirmed prion disease on sections from, respectively, 23 
and 10 brain regions. The monoclonal antibody 3F4 (1:400, 
Table 1  Comparison of diagnostic accuracy of CSF biomarkers
* T-tau >1250 pg/ml




n positive/n total Sens. (%) Spec. (%) n positive*/n 
total
Sens. (%) Spec. (%) n positive/n total Sens. (%) Spec. (%)
Definite sCJD 155/186 83.3 164/186 88.2 148/179 82.7
Probable sCJD 80/97 82.5 90/97 92.8 77/97 79.4
Possible sCJD 24/29 82.8 24/29 82.8 22/29 75.9
Definite VPSPr 1/1 1/1 0/1
Codon 129
 MM 172/195 88.2 176/195 90.3 160/190 84.2
 MV 42/72 58.3 60/72 83.3 52/72 72.2
 VV 46/46 100 46/46 100 35/44 79.5
Genetic CJD 38/46 82.6 42/46 91.3 42/46 91.3
Mutation type
 E200K-129M 11/16 68.7 13/16 81.2 16/16 100
 V210I-129M 20/21 95.2 21/21 100 20/21 95.2
 E200K-129V 4/4 100 4/4 100 4/4 100
 4-inserts-129M 1/1 1/1 1/1
 D178N-129V 1/2 1/2 0/2
 R208H-129V 0/1 1/1 0/1
 V203I-129M 1/1 1/1 1/1
All CJD** 298/359 83.0 321/359 89.4 289/352 82.1
Definite CJD 194/233 83.3 207/233 88.8 190/225 84.4
All non-CJD 118/703 83.3 84/703 88.1 2/348 99.4
“Definite” non-
CJD
79/212 62.7 54/212 74.5 1/163 99.4
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Signet Labs, MA, USA) was used for PrP immunohisto-
chemistry, as described [50], whereas the antibodies 4G8 
(1.5000, Signet Labs, MA, USA) and AT8 (1:100, Innoge-
netics, Gent, Belgium) were used to assess, respectively, 
Aβ and p-tau immunoreactivity. Neuropathological diag-
nostic assessments were done by one experienced neuro-
pathologist (PP) in virtually all cases (278 of 284 brains).
Assessment of amyloid‑beta brain deposits in CJD
For the correlation between CSF Aβ42 concentration and 
Aβ tissue deposits, brains (n = 118) were examined inde-
pendently by two evaluators (PP and HK) for the extent and 
topographic progression of Aβ pathology (Thal phases) as 
described [3]. The median time interval between lumbar 
puncture and death in this group was 2 months (interquar-
tile range (IQR) 1–4.4). To take into account the variability 
of Aβ load within brains with the same Thal phase, as well 
as the contribution of CAA, we carried out a semiquantita-
tive assessment of brain Aβ load within each of the exam-
ined brain regions (frontal, temporal, parietal and occipital 
lobes, amygdala, striatum, hippocampus (CA1 region), 
midbrain and cerebellum). Parenchymal Aβ pathology 
was graded (0–7) as follows: 0, entirely negative; 2, rare/
sparse deposits; 4, moderate number of deposits; 6, multi-
ple deposits, disseminated. An additional point was added 
to the total score if core-plaques were also noted. CAA 
was graded (0–3) as follows: 0, entirely negative; 1, up to 
two vessels focally involved; 3, more than half of vessels 
involved or significant involvement of capillaries; 2, inter-
mediate between 1 and 3. CAA was assessed in leptome-
ninges and parenchyma of all hemispheric lobes, amygdala, 
striatum, hippocampus/parahippocampal gyrus, midbrain 
and cerebellum. For each case a cumulative score (0–90) 
of total semi-quantitatively assessed Aβ load in the brain 
(parenchymal + angiopathy) was calculated.
Semi‑quantitative evaluation of primary age‑related 
(PART)/AD‑related tau pathology
For the assessment of PART/AD-related pathology, 159 
brains (158 CJD and 1 VPSPr) were examined indepen-
dently by two evaluators (PP and HK) for the extent and 
topographic progression of tau pathology (Braak stages) 
[10, 20] as described [2], with some modifications. Spe-
cifically, p-tau immunoreactivity was evaluated semi-
quantitatively (0-no immunoreactivity; 1-mild; 2-mod-
erate; 3-prominent immunoreactivity) in the following 
regions: CA1 region of the hippocampus, transentorhinal 
cortex, entorhinal cortex, parahippocampal gyrus at the 
level of anterior hippocampus, middle temporal gyrus, 
middle frontal gyrus, inferior parietal lobule, and occipital 
cortex (including the calcarine cortex). We (HK and PP) 
scored the neuronal (cell body), the fine neuritic (threads) 
tau deposits and the thick neuritis that are part of neuritic 
plaques, separately. A combined total score (0–24) was 
given to each case.
Assessment of prion‑related tau pathology
To search for tau pathology specifically related to CJD, we 
evaluated p-tau immunoreactivity in brain regions show-
ing the most prominent spongiform changes in brains with 
no or only minimal AD pathology (n = 52). To this aim, 
we excluded all cases with an AD-related tau score above 
10 or a Braak stage higher than II, and evaluated p-tau 
immunoreactivity in the cerebral cortex, anterior striatum, 
thalamus, and cerebellum. Likewise, with the AD-related 
score, a combined score was given after a semi-quantitative 
assessment (0-no immunoreactivity; 1-mild; 2-moderate; 
3-prominent immunoreactivity).
Assessment of aging‑related tau astrogliopathy (ARTAG)
ARTAG was overall defined and assessed according to 
Kovacs et al. [37]. However, a detailed topographical exam-
ination of astrocytic tau pathology was only carried out in 
the VPSPr brain, whereas in the CJD brains (n = 164) the 
analysis was limited to the screening phase, using sections 
of posterior hippocampus and pons.
PrPSc typing
PrPSc typing was performed in virtually all autopsied CJD 
cases (197/203; 180 sCJD, 16 gCJD and 1 VPSPr), using 
brain homogenates from at least four different brain regions 
(temporal, parietal, occipital cortices, and thalamus) as 
described [51, 52].
Prion disease classification
All but 6 (brain examined in a general pathology labora-
tory) sporadic cases with a definitive diagnosis were given 
a histotype classification according to the criteria proposed 
by Parchi et al. [52, 54], which are based on histopatho-
logical features, PrPSc type, and codon 129 genotype. 
Mixed sCJD types were merged with the “correspond-
ing” pure type based on similarities in the clinical phe-
notype. Accordingly, the pairs MM(V)1/MM(V)1+2C 
(from now on abbreviated in the manuscript as MM(V)1), 
MM2C/MM2C+1 (abbreviated as MM2C), and MV2K/
MV2K+2C (abbreviated as MV2K) were merged into 
three individual groups.
Genetic prion cases were classified according to the type 
of mutation and the genotype at codon 129 in the mutated 
allele (and the PrPSc type when available), while the 
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probable sCJD cases were divided into three groups based 
on the codon 129 genotype (MM, MV and VV).
Statistical analyses
CSF levels of t-tau, p-tau, the t-tau/p-tau ratio, Aβ42 and 
RT-QuIC relative fluorescence responses were analysed 
using the SPSS software package (version 20). Depending 
on the data distribution, the Mann–Whitney U test or the 
Chi-Square test were used to test differences between two 
groups, while the Kruskal–Wallis or one-way ANOVA (fol-
lowed by Tukey’s post hoc test) were applied for multiple 
group comparisons. A Bonferroni correction was applied 
to multiple comparisons. Data are expressed as median 
with IQR. The diagnostic utility of each biomarker was 
evaluated by estimating the sensitivity and specificity. ROC 
curve analysis was performed to establish the diagnos-
tic accuracy of t-tau and the t-tau/p-tau ratio. The optimal 
cut-off value for t-tau was chosen using the Youden index. 
The Youden index for a cut-off is defined by its sensitiv-
ity + specificity-1. As the distributions of values were not 
Gaussian, the Spearman bivariate test was used to detect 
the strength of correlation between the pathology scores 
and CSF levels of Aβ42 and p-tau. Values of p < 0.05 were 
considered statistically significant.
Statistical analyses of the effect of age, sex, timing of 
lumbar puncture, and disease duration on the CSF biomark-
ers were limited to the largest phenotypically homogeneous 
CJD group (e.g., MM1) when the parameter was also influ-
enced by the CJD subtype (see also “Results” section). For 
example, since it is well established that the CJD type has a 
profound effect on disease duration, the effect of this varia-
ble can only reliably be tested within a single CJD subtype.
Results
CSF 14‑3‑3
At the chosen decision point (i.e., protein band immuno-
reactivity at least two times higher than that of the weakly 
positive control), 39.2% of tested samples had a positive 
14-3-3 protein assay, including 83.3% of definite sCJD, 
82.6% of definite gCJD, 82.5% of probable sCJD and 
82.8% of possible sCJD cases (Table 1). The overall calcu-
lated test sensitivity was 83.0% and the test specificity was 
83.3%, while the test positive predictive value (PPV) and 
negative predictive value (NPV) were, respectively, 71.6 
and 90.5%. When the analysis was limited to the definite 
sCJD and the “definite” non-CJD groups the sensitivity did 
not change significantly (83.3%), whereas the specificity 
dropped to 62.7% (Table 1).
When the test sensitivity was examined in sCJD accord-
ing to the genotype at codon 129 of the PRNP gene, 
patients homozygous for valine (VV) showed the high-
est sensitivity (100%), while those carrying the heterozy-
gous methionine/valine genotype (MV) showed the low-
est (58.3%) (Table 1). The assay sensitivity varied even 
more significantly among sCJD subtypes, ranging from 0 
to 100%. It was highest and full in VV2 (100%), relatively 
high in MM(V)1 (92.8%), but low in MV2K (50.0%), very 
low in MM2C (30.0%), and inconsistent in MM2T (0%) 
(Table 2).
In the gCJD group, the test sensitivity was higher in sub-
jects carrying the V210I-129M haplotype (95.2%) than in 
those carrying E200K-129M (68.7%) (Table 1).
In the non-CJD control group, a 14-3-3 “false” positive 
result mainly occurred in patients with subacute neurologi-
cal pathologies, such as encephalitis or other inflammatory 
conditions, including paraneoplastic syndromes, or CNS 
malignancy, and, to a lesser extent, in cases affected by vas-
cular dementia/stroke or neurodegenerative dementias such 
as AD or Lewy body dementia (Table 3; Suppl. Table 3).
CSF total tau
The results of t-tau assay for the different diagnostic 
groups are summarised in the Table 1. In particular, 38.1% 
of tested samples showed t-tau levels above the cho-
sen threshold of 1250 pg/ml, including 88.2% of definite 
sCJD, 91.3% of definite gCJD, 92.8% of probable sCJD, 
and 82.8% of possible CJD cases (Table 1). The overall 
calculated test sensitivity was 89.4% and the specificity 
was 88.1%, while the PPV and NPV were, respectively, 
79.3 and 94.2%. As for 14-3-3, the sensitivity value did not 
change significantly when the analysis was limited to the 
definite sCJD and the “definite” non-CJD groups, whereas 
the specificity decreased to 74.5% (Table 1).
As with 14-3-3, the t-tau assay showed a markedly dif-
ferent sensitivity in sCJD based on the codon 129 geno-
type, the VV genotype being associated with the highest 
sensitivity (100%), and the MV genotype with the lowest 
(83.3%). Among the sCJD subtypes, the diagnostic sen-
sitivity was 100% in VV2, 92.8% in MM(V)1, 76.9% in 
MV2K, 40.0% in MM2C and 33.3% in MM2T (Table 2). 
Finally, in genetic CJD, the assay sensitivity was higher in 
patients carrying the V210I-129M haplotype (100%) than 
in those carrying E200K-129M (81.2%).
Comparison of t-tau levels among the different sCJD 
groups largely correlated with the diagnostic sensitivity 
rates outlined above. Specifically, VV and MM homozy-
gotes showed significantly higher tau levels than MV 
patients (MM vs. MV p < 0.001; VV vs. MV p < 0.001). 
Furthermore, t-tau protein levels were significantly higher 
in sCJD subtypes VV2 (8478, IQR 5422–12350) and 
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MM(V)1 (6848, IQR 3302–11300) than in the MV2K 
(2012, IQR 1405–3083), MM2C (1084, IQR 858–1713) 
and MM2T subtypes (310, 630, and 1377 pg/ml in the three 
cases examined) (Fig. 1) (MM(V)1 vs. MV2K p < 0.001; 
MM(V)1 vs. MM2C p < 0.001; VV2 vs. MV2K p < 0.001; 
VV2 vs. MM2C p < 0.001). Finally, patients carrying the 
V210I-129M haplotype showed significantly increased 
CSF t-tau levels (6735, IQR 3412–11000) compared to 
subjects carrying the E200K-129M haplotype (2205, IQR 
1344–3114) (p < 0.001).
Among the false-positive cases, the diagnostic category 
CNS malignancy had the highest relative incidence, fol-
lowed by encephalitis, vascular dementia and AD (Table 3; 
Suppl. Table 3).
RT‑QuIC assay
The results of the RT-QuIC assay for the different diagnos-
tic groups are summarised in Table 1. At the chosen thresh-
old 82.7% of definite sCJD, 91.3% of definite gCJD, 79.4% 
of probable sCJD and 75.9% of possible sCJD cases had 
a positive RT-QuIC assay (Table 1). The overall calculated 
test sensitivity (all CJD vs. non-CJD) was 82.1% and the 
test specificity was 99.4%, while the test PPV and NPV 
were, respectively, 99.0 and 84.4%.
RT-QuIC sensitivity in sCJD varied according to the 
codon 129 genotype and was higher in MM (84.2%) than 
in MV (72.2%) or VV (79.5%) subjects. Consistently, sub-
jects affected by the prevalent MM(V)1 subtype showed a 
higher sensitivity than those affected by any of the atypical 
disease subtypes (Table 2). However, there was no relation-
ship between codon 129 genotype or disease subtype and 
either the lag phase or the maximal fluorescence signal 
response recorded during the RT-QuIC analysis among pos-
itive cases (data not shown). Furthermore, patients carrying 
the E200K-129M haplotype had a higher RT-QuIC sensitiv-
ity (100%) than those carrying V210I-129M (95.2%), which 
correlated with a significantly shorter lag phase in the for-
mer group (Fig. 2). Among the subjects carrying other rarer 
mutations, only the patient with the V203I substitution gave 
a positive response (Table 1). Genetic CJD patients carry-
ing E200K-129M showed a slightly increased maximal 
ThT signal (14289, IQR 9742–16006) compared to both 
gCJD carrying V210I-129M (12720, IQR 9095–16696) and 
sCJD MM(V)1 subjects (12140, IQR 9400–15787), but the 
difference did not reach statistical significance.
Overall, the specificity of RT-QuIC was substantially 
better than that of CSF 14-3-3 or t-tau. Only two CSF 
samples from the non-CJD group gave a positive RT-
QuIC response. This first CSF was from a patient with a 
RPD and a clinical diagnosis of paraneoplastic syndrome 
(a metastatic breast carcinoma was found) who had a posi-
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disease duration of 4 months. The second patient, who was 
lost to follow-up, was referred with a clinical diagnosis of 
suspected FTD (clinical symptoms, neuropsychological 
tests and FDG-PET demonstrated a predominant fronto-
temporal involvement) after a relatively rapid clinical 
course of about 1.5 years. Results of diagnostic investiga-
tion included a negative standard (no DWI sequence) cer-
ebral MRI, a negative 14-3-3 test, increased t-tau (1362 pg/
ml) and p-tau levels (154 pg/ml) and reduced Aβ42 
(369 pg/ml).
CSF p‑tau and the t‑tau/p‑tau ratio
CSF p-tau levels were significantly higher in AD patients 
(87, IQR 72–117; n = 85) than in CJD (49, IQR 36–67; 
n = 294) and the other non-CJD patients (48.5, IQR 30.8–
75; n = 226) (AD vs. CJD p < 0.001; other non-CJD vs. 
CJD p = 0.744; AD vs. other non-CJD p < 0.001).
Interestingly, p-tau levels varied significantly among 
sCJD subtypes, with both VV2 (67, IQR 62–94; n = 27) 
and MV2K (64.5, IQR 46.8–94; n = 24) patients showing 
significantly higher levels than MM(V)1 (43, IQR 34–58; 
n = 103) (p < 0.001) or MM2C cases (26, IQR 19–52; 
n = 10) (p < 0.001) (Fig. 3). In the gCJD group, there were 
no significant differences in p-tau levels between V210I-
129M and E200K-129M carriers (p = 0.111), while the 
single case of VPSPr showed one of the highest CSF p-tau 
levels of the prion disease group (140 pg/ml).
As previously reported, CJD patients present with 
a significant increase in the t-tau/p-tau ratio (97.5, IQR 
42.6–185.7; n = 294) in comparison to both AD (7.9, IQR 
6.7–10.2; n = 85) and other non-CJD (15.2, IQR 8.0–
31.2; n = 226) subjects (CJD vs. AD p < 0.001; CJD vs. 
non-CJD p < 0.001; AD vs. non-CJD p < 0.001). Results 
from the ROC analysis for t-tau/p-tau ratio are illus-
trated in Fig. 4. The t-tau/p-tau ratio achieved an AUC 
of 0.907 ± 0.013 in the discrimination of CJD from all 
Table 3  Influence of diagnostic category on false positive results: 14-3-3 vs t-tau
NDG neurodegenerative
a 21/58 patients improved at follow-up
b 2 patients improved at follow-up
c All these patients improved at follow-up
Diagnostic categories of non-CJD patients 14-3-3 positive/total (%) t-tau positive/total (%) Definitive diagnosis 
(n = 212)
Path. Clin.
Alzheimer’s disease 8/101 (7.9) 16/101 (15.8) 15 1
Lewy body dementia 4/72 (5.6) 5/72 (6.9) 13 1
Frontotemporal dementia 3/40 (7.5) 3/40 (7.5) 0 2
Other NDG diseases 1/51 (2.0) 0/51 (0) 1 3
Mixed dementia 0/35 (0) 0/35 (0) 1 0
Vascular dementia/stroke 19/85 (22.4) 15/85 (17.6) 11 7
CNS malignancy 11/18 (61.1) 5/18 (27.8) 8 8
Encephalitis/paraneoplastic syndromes 52/130 (40.0) 24/130 (18.5) 14 58a
Toxic/metabolic encephalopathy 2/20 (10.0) 1/20 (5.0) 4 6b
Psychiatric disease 0/8 (0) 0/8 (0) 0 4
Other diseases 0/13 (0) 0/13 (0) 1 3
Cause unknown 18/130 (13.8) 15/130 (11.5) 13 38c
Fig. 1  Effect of sCJD subtype on t-tau CSF levels. T-tau protein lev-
els were significantly higher in sCJD VV2 (n = 29), and MM(V)1 
(n = 111) subtypes than in the MV2K (n = 26) and MM2C (n = 10) 
subtypes (MM(V)1 vs. MV2K p < 0.001; MM(V)1 vs. MM2C 
p < 0.001; VV2 vs. MV2K p < 0.001; VV2 vs. MM2C p < 0.001)
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non-CJD with 84% sensitivity and 83% specificity, using 
a cut-off value of 31.8. The ROC analysis for t-tau alone 
on the same patient population (n = 294 CJD and 311 
non-CJD) showed a similar AUC value (0.904 ± 0.013). 
However, the calculated AUC of the t-tau/p-tau ratio in 
the distinction between CJD and non-CJD, after exclud-
ing the AD patients, was lower than the one for t-tau 
alone in the same group of patients (0.876 ± 0.016 vs. 
0.892 ± 0.015). Details on the numbers of non-CJD sam-
ples used for the p-tau assay for each diagnostic category 
are provided in Suppl. Table 4.
We also found statistically significant differences in 
the t-tau/p-tau ratio among the different sCJD subtypes. 
The MM(V)1 group showed the highest values (158.41, 
IQR 74.0–220.9; n = 103), followed by the VV2 (110.8, 
IQR 90.7–148.8; n = 27), MM2C (49.6, IQR 19.2–59.1; 
n = 10), and MV2K (26.4, IQR 20.9–51.7; n = 24) 
groups (MM(V)1 vs. MV2K p < 0.001; MM(V)1 vs. 
MM2C p < 0.001; VV2 vs. MV2K p < 0.001).
Fig. 2  Time course of prion seeding detected by RT-QuIC in CSF of 
sCJD MM(V)1, gCJD E200K-129M and gCJD V210I-129M. a Aver-
aged RT-QuIC kinetics for sCJD MM1 and gCJD (E200K-129M or 
V210I-129M haplotypes) CSF samples. Traces represent the mean 
(±standard error of the mean [SEM]) of ThT fluorescence for CSF 
specimens from representative groups of patients with sCJD MM1 
(black, n = 50), gCJD E200K-129M (red, n = 10) and gCJD V210I-
129 M (blue, n = 10). b Box plots of the times to threshold (as 
defined in the “Materials and methods”) for sCJD MM(V)1 (n = 90), 
gCJD E200K-129M (n = 16) and gCJD V210I-129M (n = 20) CSFs 
with a positive RT-QuIC assay. Statistically significant differences 
were found when comparing gCJD E200K-129M vs. sCJD MM(V)1 
(p < 0.001) or vs. gCJD V210I-129M (p < 0.001)
Fig. 3  Effect of sCJD subtype on p-tau CSF levels. VV2 (n = 27) 
and MV2K (n = 24) patients showed significantly higher p-tau levels 
than MM(V)1 (n = 103) or MM2C (n = 10) cases (VV2 vs. MM(V)1 
p < 0.001; MV2K vs. MM(V)1 p < 0.001; VV2 vs. MV2K p = 0.308; 
VV2 vs. MM2C p < 0.001; MV2K vs. MM2C p < 0.001)
Fig. 4  ROC analysis for t-tau/p-tau ratio. The t-tau/p-tau ratio 
achieved an area under the curve of 0.907 ± 0.013 in the discrimina-
tion of all CJD (n = 294) from all non-CJD (n = 311) with 84% sen-
sitivity and 83% specificity, using a cut-off value of 31.8
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Correlation between CSF p‑tau levels and tau 
neuropathology
Analysis of prion‑related tau pathology
To search for abnormal tau deposits specifically related 
to CJD pathology, we evaluated p-tau immunoreactivity 
in brain regions showing the most prominent spongiform 
change in subject with no or only minimal AD-related 
changes. An initial screening revealed the presence of a 
dot- or stub-like positive immunoreactivity (Fig. 5) in most 
of the examined cases. However, the number and, to some 
extent, the size of the abnormal tau-deposits varied sig-
nificantly among cases, often irrespectively of the degree 
of spongiform change, and was clearly correlated with the 
CJD type (see below). Furthermore, in all CJD types, the 
dot- or stub-like p-tau deposits were rarely detected, or not 
seen at all, in the cases with severe neuronal/neurophil loss 
and reactive gliosis. In a selected group of 50 cases with 
typical spongiform change and mild to moderate neuronal 
loss, we found a highly significant positive correlation 
between the amount of this prion-specific tau deposition 
and p-tau levels in the CSF (r = 0.564, p < 0.001; n = 50) 
(Fig. 6a). Consistently, brains from both VV2 (6, IQR 4–7; 
n = 21) and MV2K (7, IQR 4–8; n = 10) cases showed 
a significantly higher score of positive immunoreactivity 
than those from MM(V)1 cases (1.5, IQR 1–3; n = 19) 
(MM(V)1 vs. VV2 p < 0.001; MM(V)1 vs. MV2K 
p < 0.001; MV2K vs. VV2 p = 0.699) (Fig. 6b). The cor-
relation between the distribution of spongiform change and 
the presence of the abnormal p-tau deposits was particu-
larly striking in the cerebral cortex of VV2 cases in which 
both lesions often co-distributed in a laminar pattern only 
involving the deep cortical layers (Fig. 5a and d). The anal-
ysis of 5 genetic CJD cases (E200K and V210I mutations) 
did not reveal significant differences in the extent of prion-
specific tau deposition in comparison to the sporadic cases 
of the same MM(V)1 type. 
Analysis of AD‑related tau pathology
To determine the effect of AD-related tau pathology to the 
CSF levels of p-tau we focused on the CJD MM(V)1 cases, 
the largest homogeneous group available (n = 109 brains) 
and the one showing the least amount of prion-specific tau 
pathology (see above). The median time interval between 
lumbar puncture and death in this group was 1.3 months 
(IQR 0.5–2.5). Within the group, we found a significant 
positive correlation between CSF p-tau levels and the AD-
pathology score (r = 0.366, p < 0.001) (Fig. 7a). Thus, 
CSF p-tau levels in CJD also reflect the extent of co-mor-
bid neurofibrillary AD pathology. We also correlated CSF 
Fig. 5  Immunohistochemistry for p-tau (AT8 antibody) in brain 
regions showing spongiform change in sporadic CJD VV2, MV2K, 
and VPSPr. Dot- and stub-like tiny tau deposits in the deep layers of 
the temporal neocortex (a = ×400; d = ×1000), and in the thalamus 
(c = ×400; e = ×1000) of a sCJD VV2 case, and in the anterior stri-
atum (b = ×400) of a sCJD MV2K; cluster of granular-fuzzy astro-
cytes in the cerebral cortex of the VPSPr case (f ×400)
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p-tau concentrations with Braak stages and found that 
stages III–V were linked to abnormal, above threshold 
(60 pg/ml), p-tau CSF levels in the majority (71%) of cases 
(69, IQR 54–81; n = 14), whereas the majority (84%) of 
brains with Braak stage I–II were associated with CSF val-
ues of p-tau within the range of controls (48, IQR 35–57; 
n = 37), although with slightly higher median values than 
those in Braak stage 0/+ (40, IQR 33–51; n = 58). Con-
sistently with the CSF findings, no significant differences 
(p = 0.529) in the AD-pathology score were seen between 
sporadic (4, IQR 1–10.5; n = 95) and genetic (5, IQR 
0–6.5; n = 14) CJD cases of the MM(V)1 type.
To address whether a higher degree of neuronal 
AD related tau pathology (in comparison to the other 
subtypes), besides the tiny neuritic tau profiles, could 
have contributed to the increased of p-tau levels in 
sCJD VV2 and MV2K, we also compared the relative 
distribution of Braak stages and of the mean AD-related 
score among the major disease subtypes. The finding of 
a trend towards a higher degree of AD pathology in the 
MM(V)1 (see Suppl. Table 5) excluded this possibility. 
To the same aim, we also screened the posterior hip-
pocampus for glial tau pathology and found evidence for 
ARTAG (subependymal type in focal clusters) in a lim-
ited number of CJD cases (7 out of 158, 4.5%), belong-
ing to both the MM(V)1 and VV2 subtypes (see Suppl. 
Table 5). Thus, the relative rarity of ARTAG in both our 
series, and the one studied by Kovacs et al. (6.6% in a 
CJD population with a mean age of 72 yrs) [36], with no 
apparent difference in frequency between MM(V)1 and 
VV2/MV2K cases, also excludes a significant specific 
contribution of ARTAG to the increased CSF p-tau levels 
we have found in VV2 and MV2K cases.
CSF Aβ42 and correlation with the Aβ load in the brain
Overall, the Aβ42 concentration was significantly lower 
in AD patients (326, IQR 274–394; n = 61) than in the 
CJD group (508, IQR 360–717; n = 164) and the other 
non-CJD groups (514, IQR 279–799; n = 60) (AD vs. 
CJD p < 0.001; AD vs. non-CJD p < 0.001; other non-
CJD vs. CJD p = 0.926). Among CJD samples there was 
no significant difference among sCJD subtypes or gCJD 
cases carrying the V210I-129M or the E200K-129M 
haplotypes.
Among the definite sporadic and genetic CJD cases 
examined for the correlation between CSF Aβ42 concentra-
tion and Aβ brain deposits (n = 118), the median time inter-
val between lumbar puncture and death was 2 months (IQR 
1–4.4). Forty-five brains showed no Aβ deposits (score = 0). 
In this cohort, the median Aβ42 level was 579 pg/ml (IQR 
369–754), with 38% of patients (17/45) having CSF Aβ42 
levels below the threshold of 450 pg/ml, whereas in those 
with Aβ brain deposits (n = 73), the Aβ score showed a signif-
icant inverse correlation with CSF Aβ42 levels (r = −0.354, 
p = 0.002) (Fig. 7b). Thus, CSF Aβ42 levels in CJD reflect 
both CJD-related pathology and the extent of co-morbid AD 
pathology. We also correlated CSF Aβ42 levels with the Thal 
phase, and found that only the brains with advanced phases 
(IV or V) showed abnormal, below threshold, Aβ42 CSF 
levels in almost all cases (82%; 402, IQR 277–479; n = 17), 
whereas the majority (68%) of those in phases I–III showed 
CSF values of Aβ42 within the range of controls (575, IQR 
439–703; n = 54) (Fig. 8). Finally the two cases with pure 
(mild) CAA and no parenchymal Aβ deposits showed Aβ42 
CSF levels within the normal range (956 and 550 pg/ml).
Fig. 6  Correlation between CSF p-tau levels and PrP-tau score. a 
A significant positive correlation is seen between p-tau levels in the 
CSF and the amount of prion-specific tau deposition in the brain 
(r = 0.564, p < 0.001; n = 50); b Brains from both VV2 (6, IQR 
4–7; n = 21) and MV2K (7, IQR 4–8; n = 10) cases showed a sig-
nificantly higher score of positive immunoreactivity than those from 
MM(V)1 cases (1.5, IQR 1–3; n = 19) (MM(V)1 vs. VV2 p < 0.001; 
MM(V)1 vs. MV2K p < 0.001; MV2K vs. VV2 p = 0.699)
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Correlation of CSF and brain findings in VPSPr
The high CSF p-tau levels (140 pg/ml) and the low Aβ42 
levels (402 pg/ml) in the single case of VPSPr examined 
in this study correlated with a significant brain Aβ load 
(Thal phase IV, Aβ score 37) and a mixed brain tauopathy 
comprising features of PART/AD (Braak stage III, AD-tau 
score 15), prion-related tauopathy (PrP-tau score 3.5) and 
ARTAG. Specifically, the following types of ARTAG were 
seen: gray matter type; regions involved: MTL, lobar, sub-
cortical, and brainstem; extent: occasional, solitary or in 
focal clusters (Fig. 5f); plus laminar subpial type; regions 
involved: MTL, lobar, subcortical, and brainstem; extent: 
numerous, multifocal; plus subependymal type, regions 
Fig. 7  Correlations between CSF p-tau and Aβ42 levels and AD-
related neuropathology in CJD MM(V)1. a A significant positive 
correlation is seen between CSF p-tau levels and the AD-pathology 
score (r = 0.366, p < 0.001; n = 109). b A significant inverse cor-
relation is seen between CSF Aβ42 levels and the Aβ pathology score 
(r = −0.354, p = 0.002; n = 73)
Fig. 8  Examples of imperfect correlation between CSF Aβ42 lev-
els and extent of Aβ brain deposits in CJD. Various Aβ aggregates 
(plaques) in CJD brains (a–f); a sCJD MM1+2C, temporal cortex, 
Thal phase III, AD-score = 31, CSF Aβ42 = 704 pg/ml, magnifica-
tion ×100; b, c sCJD MV2K, parietal cortex (b) and striatum (c), 
Thal phase III, AD-score = 45, CSF Aβ42 = 771 pg/ml, magnifica-
tion ×100 (b) or ×200 (c); d, e sCJD VV2, parietal cortex (d) and 
amygdala (e), Thal phase IV, AD-score = 53, CSF Aβ42 = 646 pg/
ml, magnification ×100; sCJD MM1 (f), Thal phase I, AD-score = 2, 
CSF Aβ42 = 411 pg/ml, magnification ×200
572 Acta Neuropathol (2017) 133:559–578
1 3
involved: MTL; extent: in focal clusters; plus perivascular 
and white matter types; regions involved: MTL, lobar, sub-
cortical, and brainstem; extent: in focal clusters of various 
size.
Effect of age, sex, timing of lumbar puncture, 
and disease duration on CSF biomarkers
Demographic characteristics for definite, probable and pos-
sible CJD are provided in Suppl. Table 6. In the group of 
definite and probable CJD patients, there was no effect of 
sex on Aβ42 (p = 0.123), p-tau levels (p = 0.496) and RT-
QuIC results (p = 0.533). In the same group, when strati-
fying p-tau, Aβ42, RT-QuIC results by age, there was no 
effect of age on Aβ42 (p = 0.061), p-tau (p = 0.115) lev-
els and RT-QuIC results (p = 0.384) (see Suppl. Table 7). 
In the group of definite sporadic MM(V)1 there was no 
effect of time from clinical onset to LP and of time from 
LP to death on Aβ42 (p = 0.691; 0.256), t-tau (p = 0.815; 
0.225), p-tau levels (p = 0.707; 0.248), 14-3-3 (p = 0.238; 
0.346), and RT-QuIC results (p = 0.210; 0.673) (see Suppl. 
Table 8). In the same group, there was no effect of disease 
duration on Aβ42 (p = 0.566), t-tau (p = 0.636), p-tau lev-
els (p = 0.515), 14-3-3 (p = 0.430) and RT-QuIC results 
(p = 0.930) (see Suppl. Table 8).
Discussion
The present study reports the results of a comprehensive 
analysis of all major available CSF biomarkers for the 
differential diagnosis of CJD in a large unselected clini-
cal population reflecting clinical practice, taking also into 
account the effect of the disease subtype on diagnostic 
accuracy and the influence of tau and Aβ brain pathology 
on p-tau and Aβ42 CSF levels.
Our results confirm the very high specificity of RT-QuIC 
for the diagnosis of sCJD in a large series of CJD and non-
CJD CSF samples. However, they also provide, for the first 
time, convincing evidence for a lower sensitivity of the 
assay in atypical subtypes of the disease characterised by 
PrPSc type 2 (e.g.,VV2, MV2K, and MM2C). The negative 
results we repeatedly obtained with the CSF samples from 
a patient affected by VPSPr and one from a GSS patient 
carrying the D202N mutation [P. Parchi, personal com-
munication] are also consistent with this finding. Thus, as 
with CSF protein surrogate markers, the in vitro conversion 
reaction exploited by RT-QuiC is significantly affected by 
the neurobiological heterogeneity of human prions.
Recent studies using a different recombinant PrP sub-
strate or olfactory mucosa brushings instead of CSF as an 
alternative seed reported a 96–97% sensitivity of the RT-
QuIC assay for the diagnosis of sCJD [45, 46]. However, 
although very promising, these novel modified RT-QuIC 
assays have, to date, only been applied to sCJD cases 
largely represented by typical CJD patients affected by the 
MM(V)1 type. Furthermore, at variance with the methodol-
ogy used in the present study [42], the modified assays have 
not been, as yet, validated in the inter-laboratory setting.
The reasons behind the variability in seeding activity 
among CSF samples from CJD patients remain, unfortu-
nately, partially unclear. Indeed, besides the above-men-
tioned correlation with the disease subtype, we failed to 
reveal other common features among the CSF samples giv-
ing a negative RT-QuIC result. In particular, there was no 
significant correlation with age at onset, disease duration 
at the time of lumbar puncture, or with the results of both 
conventional protein assays and brain MRI. Future studies 
should further address this issue and establish, in the first 
instance, whether seeding activity correlates or not with 
PrPSc levels. Nevertheless, our observation of a higher con-
version activity of the samples from gCJD patients carrying 
the E200K-129M haplotype (and PrPSc type 1), in compari-
son to those of the sCJD MM(V)1 group, which is confirm-
atory of the results of a previous study [19], supports the 
view of a direct role of PrPSc in seeding rec-PrP conversion 
and aggregation.
Regarding the more conventional CSF surrogate diag-
nostic markers, such as proteins t-tau and 14-3-3, our data 
demonstrate that t-tau is (moderately) superior to 14-3-3 
in the diagnosis of sCJD. More specifically, t-tau yields a 
lower number of false positive results, especially in cases 
suffering from inflammatory-related conditions and suba-
cute dementias; moreover, it has a higher sensitivity than 
14-3-3 for the sCJD MV2K type. These results, which are 
in line with those reported by Hamlin et al. [30], together 
with the notion that the t-tau assay has technical advantages 
with respect to the standard western blot 14-3-3 assay, sug-
gest a change in the current recommendations to prioritise 
t-tau analysis over 14-3-3. Interestingly, t-tau appears to be 
less accurate than 14-3-3 only in the differential diagnosis 
with AD; however, in cases where the differential diagno-
sis with AD is an issue, biomarker analysis can also take 
advantage of Aβ42 and p-tau and possibly total-PrP dos-
age, allowing for the calculation of t-tau/p-tau and other 
ratios based on different combinations of these four bio-
markers, which have been reported to significantly improve 
diagnostic accuracy in such cases [1, 21, 67]. Outside this 
specific clinical scenario (CJD vs rapidly progressive AD), 
however, our data do not support the additional diagnostic 
value of t-tau/p-tau ratio with respect to t-tau alone. This 
lower diagnostic performance of t-tau/p-tau ratio com-
pared to what is generally reported in the literature [9, 12, 
21, 60, 67] likely reflects differences in the characteristics 
of the examined patient populations. Indeed, while previ-
ous studies mainly analysed the diagnostic accuracy of 
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the t-tau/p-tau ratio in the differential diagnosis between 
typical CJD and AD or between CJD and large clinically 
unselected populations of patients with dementia, our study 
focused on patients referred for the suspicion of CJD and 
included a relatively high number of CJD cases of less 
common subtypes such as VV2, MV2K and MM2C, show-
ing a significantly lower t-tau/p-tau ratio than the typical 
CJD MM(V)1.
Our results further underline the profound implica-
tions that the phenotypic heterogeneity of the disease has 
on diagnostic criteria and the overall clinical approach to 
a patient suspected of having CJD. Indeed, as also clearly 
revealed by our study, the sensitivity of both surrogate pro-
tein markers and RT-QuIC varies significantly according 
to the CJD type. Given that knowledge about the patient’s 
PRNP codon 129 genotype, one of the two major molecu-
lar determinants of the disease type, can be obtained from 
a blood sample, it is crucial to include codon 129 genotyp-
ing in the diagnostic work-up of patients with suspected 
CJD. This information, combined with those obtained from 
the patient’s clinical history and neurological examina-
tion, which is usually able to discriminate between a typi-
cal (MM(V)1) or atypical (all the others) disease subtype 
are crucial for the correct interpretation of the results of 
CSF assays. The most striking example of the importance 
of codon 129 genotyping for the clinical diagnosis of CJD 
concerns the VV2 subtype, the second most common sCJD 
type [53]. Given the relatively uniform and consistent clini-
cal phenotype early in the disease course in these subjects, 
and the 100% sensitivity of standard CSF assays, the find-
ing of VV at codon 129 in such a clinical scenario is highly 
confirmatory of the diagnosis of sCJD, even in cases with a 
negative RT-QuIC result. In contrast, the finding of a nega-
tive 14-3-3 test and/or t-tau levels below 1250 pg/ml in a 
codon 129 VV patient will exclude the diagnosis of sCJD 
VV2 with a 100% NPV.
One of the major issues in the field of diagnostic bio-
markers concerns their correlation with the underlying 
brain pathology. Besides the analyses of the effect of CJD 
subtypes on all biomarkers analysed, in this study we have 
correlated neuropathological and CSF findings for both 
p-tau and Aβ. Our findings of increased CSF p-tau concen-
trations in sCJD types VV2 and MV2K, (both caused by 
CJD strain V2), is of particular significance in this respect. 
Indeed, although the CSF tau profile in CJD patients usu-
ally combines excessively high t-tau with relatively low 
p-tau concentrations [21, 57, 67, 68], we and other authors 
have clearly shown that CSF p-tau levels can be signifi-
cantly raised in prion disease too, owing, once again, to the 
heterogeneity of the disease. In previous studies, variant 
CJD subjects showed raised CSF p-tau in most cases [29], 
and elevated levels of CSF p-tau have also been detected 
in VPSPr and GSS [56], as also shown in individual cases 
in the present study. Interestingly, a secondary tauopathy 
characterised by brain deposition of abnormal p-tau aggre-
gates has been demonstrated in all these atypical pheno-
types of prion disease by post-mortem studies [26, 27, 31, 
58], although the data on VPSPr are very limited. Thus, our 
CSF findings raise the question of whether a tauopathy in 
response to PrPSc deposition also develops in classic CJD, 
especially in the VV2 or MV2K subtypes. Initial stud-
ies were either negative [27 or led to the conclusion that 
only prion diseases associated with PrP-amyloid plaques 
develop p-tau deposits, whereas those characterised by 
synaptic PrP deposits do not [66]. More recently, Reiniger 
et al. [59] demonstrated that a tiny punctate (also described 
as rod-, dot-, or stub-shaped), PrP-specific, p-tau immuno-
reactivity, positively correlating with PrPSc burden in the 
neocortex, is consistently found in sCJD brains, irrespec-
tive of the molecular subtypes and the AD-related associ-
ated pathology. Consistently, in a recent study by Kovacs 
et al. [36] these small neuritic profiles were regarded as the 
most frequent type of tau immunoreactivity in CJD brains. 
Pursuing the findings of these studies we demonstrated 
here, for the first time, that in classic CJD the prion-specific 
secondary tauopathy especially affects the sCJD subtypes 
linked to the V2 strain (e.g., VV2 and MV2K) and, most 
significantly, that in such cases the tauopathy is severe 
enough to determine a significant increase in p-tau levels 
in the CSF. Furthermore, we reported the detection of prion 
specific p-tau dots in VPSPr, a finding we have confirmed 
in a second case, for whom we had no CSF [P. Parchi per-
sonal communication]. Small neuritic p-tau positive pro-
files have been, to date, only documented in the frontal 
cortex of a single case of VPSPr [4]. Overall, our results 
expand on but also help, to some extent, to understand 
some of the previous findings. Indeed, the fact that both 
VV2 and MV2K are sCJD types characterised by plaque-
like PrP deposits or even PrP-amyloidosis (MV2K) and 
are associated, on average, with a higher PrPSc burden than 
those of the MM(V)1 type [49] somehow fits with the data 
of both Sikorska et al. [66] and Reiniger et al. [59]. Moreo-
ver, our observation that the PrP-related tau deposits were 
rarely detected in the cases with severe neurodegeneration 
also explains the previously described lack of correlation 
between tau deposits and disease duration [59].
Aβ42 concentration in the CSF of sCJD patients has 
been measured in a number of studies, but with incon-
sistent results [21, 34, 47, 71, 73, 75, 77]. Early studies, 
based on a limited number of cases, found significantly 
decreased Aβ42 levels in CSF of CJD patients with mean 
values comparable to those of AD patients and with no 
apparent correlation with either the APOE genotype or 
the number of Aβ-positive plaques in the brain [34, 47, 
71]. More recently, however, Varges et al. [73] dem-
onstrated a dose-dependent effect of APOE-4 on the 
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decrease in Aβ42 in the CSF of sCJD patients. Further-
more, other preliminary data suggest that Aβ42 levels in 
the CSF are significantly higher in sCJD than in AD. In 
the present study we definitely show, in a large group of 
sCJD cases, that (1) the CSF levels of Aβ42 are signifi-
cantly higher in sCJD than in AD and that (2) about 60% 
of sCJD cases have a concentration of Aβ42 in the CSF 
within the range of controls. Nevertheless, our analyses 
of Aβ load in neuropathologically verified patients clearly 
shows that the decrease in CSF Aβ42 in CJD patients, 
although influenced by the co-morbid AD pathology, 
may occur irrespective of the plaque load. Thus, the more 
likely explanation for the reduced Aβ42 levels in a sub-
group of sCJD patients seems to be a combined effect of 
age-related co-morbidity, influenced by the APOE geno-
type, and the effect of neuronal loss which can be very 
significant in CJD even a few months after clinical onset. 
An alternative explanation, which has been put forward 
in previous studies [47, 75], indicates that in pathologic 
conditions such as CJD a fraction of Aβ42 cannot be 
detected by conventional ELISA methods as epitopes 
may be masked.
Our findings have also implications for the issue of CSF 
biomarkers reliability in AD. Indeed, at variance with most 
neurodegenerative disorders including AD, brains affected 
by CJD and other rapidly progressive dementias provide 
the unique opportunity to correlate the CSF findings with 
the post-mortem neuropathology within a short time inter-
val. Although our data confirm an overall positive correla-
tion between p-tau levels in the CSF and the extent of brain 
tauopathy and an inverse correlation between Aβ42 levels 
and β-amyloid load, it must be emphasized that the cor-
relation for Aβ42 and β-amyloid is rather gross. Of most 
significance in this respect, also given the “negative” effect 
of CJD on Aβ42 concentration in the CSF, is our finding 
of Aβ42 levels within the control range in 68% of CJD 
brains with a co-occurring significant Aβ deposition in the 
brain (Thal phases I–III). If confirmed in brains with other 
pathologies, this finding would suggest that the Aβ42 level 
in the CSF is far from being an optimal marker of the early 
phases of Aβ deposition in the brain in pre-clinical AD. 
Given that our data are limited to Aβ42, it will be impor-
tant to expand the correlative analysis to other Aβ peptides 
such as Aβ40. Indeed, evidence suggests a better diagnostic 
performance of the Aβ42/40 CSF concentration ratio com-
pared to the Aβ42 concentration alone [39, 76]. Further-
more, although AD typically affects both cerebral hemi-
spheres to a similar degree, the fact we have only examined 
one hemisphere might be considered as a potential limita-
tion of our study.
At variance with Aβ42, according to our data, CSF 
p-tau level represents a more reliable marker of brain 
AD-related tau pathology since it fails to consistently 
discriminate between patients with or without neurofibril-
lary pathology only when p-tau deposition is relatively 
mild and limited to the transentorhinal/entorhinal cortices 
(Braak stages I–II).
In summary, our study provides confirmatory and 
novel evidence for a significantly improved value of CSF 
biomarkers for the clinical diagnosis of CJD. Although 
RT-QuIC is the most promising assay, given its high 
specificity, t-tau remains the most important surrogate 
marker. Our data support a change in the current diagnos-
tic criteria for CJD, indicating both RT-QuIC and t-tau as 
primary laboratory investigations to be implemented in 
suspected cases of CJD, in combination, when possible, 
with codon 129 genotyping. In cases of a negative RT-
QuIC result and elevated t-tau in a patient with rapidly 
progressive cognitive impairment, the differential diag-
nosis between CJD and atypical AD is also supported by 
the combined analyses of CSF p-tau, Aβ42 and possibly 
total-PrP [1, 21]. Finally, in cases with a negative RT-
QuIC result the determination of CSF t-tau in combina-
tion with codon 129 genotyping remains of importance 
for the clinical diagnosis of sCJD VV2.
Despite the significant advances, the diagnostic value 
of both CSF biomarkers and cerebral MRI remain very 
low in some rare atypical variants of sporadic prion 
disease, such as sporadic fatal insomnia (MM2T) and 
VPSPr. Efforts should continue in the attempt to recog-
nise such atypical forms through disease surveillance and 
the neuropathological examination of suspected cases. 
Future studies should also aim to develop a type-specific 
RT-QuIC or other assay to discriminate the molecular 
subtypes of sCJD cases in vitam to bring the epidemio-
logical surveillance of sCJD to the next level.
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